SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Grant of Options and Additional Listing

20 Nov 2013 17:00

RNS Number : 5694T
Silence Therapeutics PLC
20 November 2013
 



 

20 November 2013

 

Grant of Options and Additional Listing

On 19 November 2013, Tim Freeborn (Finance Director and Company Secretary) and Annie Cheng (Chief Operating Officer) were granted 40,000 and 76,000 options respectively over ordinary shares of 5 pence. The share options, granted at nil consideration, will vest after three years and are exercisable at 282 pence per share (the previous day's closing price), and are subject to a 400p hurdle price.

Following this grant of these options, Tim Freeborn and Annie Cheng hold the following total number of options over ordinary shares of Silence Therapeutics:

No. of Options

Tim Freeborn

310,000

Annie Cheng

140,000

 

The Company also announces that it has applied to AIM for the admission to trading of 48,000 Ordinary Shares of 5 pence each in the company. These shares are being issued in respect of an exercise of options under the Employee Share Scheme, at an exercise price of 90 pence per share.

Admission of these shares is expected to take place on Monday 25 November 2013. The total number of shares in issue, following admission, will be 47,061,554.

For further information please contact:

 

Silence Therapeutics plc

Ali Mortazavi, Chief Executive

+44 (0)333 988 0140

a.mortazavi@silence-therapeutics.com

Timothy Freeborn, Finance Director

t.freeborn@silence-therapeutics.com

Annie Cheng, Chief Operating Officer

 

a.cheng@silence-therapeutics.com

Canaccord Genuity Limited

+44 (0)20 7523 8350

Lucy Tilley

Dr Julian Feneley

Henry Fitzgerald-O'Connor

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
LISEAKFEASNDFFF

Related Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Back to RNS